Long‐term effectiveness of <scp>iGlarLixi</scp> treatment in people with type 2 diabetes in the United States: The soli‐durability 24‐month observational study
iGlarLixi initiation was associated with improved glycaemic control, without body weight change or increased hypoglycaemia over 24 months.
Authors
- Mine Adaş (ORCID: https://orcid.org/0000-0003-3008-6581)
- Felipe Lauand
- Rayaz Ahmed Malik (ORCID: https://orcid.org/0000-0002-7188-8903)
- Giuseppina Tiziana Russo (ORCID: https://orcid.org/0000-0002-4565-3131)
- John Anderson (ORCID: https://orcid.org/0000-0003-3578-8064)
- Kamlesh K. Khunti (ORCID: https://orcid.org/0000-0003-2343-7099)
- Xuan Li (ORCID: https://orcid.org/0000-0001-5781-1662)
- M.E.A. Amani
- Agustina Alvarez
Institutions
- University of Messina (IT)
- Université Oran 1 Ahmed Ben Bella (DZ)
- University of Leicester (GB)
- Sanofi (France) (FR)
- Sanofi (Spain) (ES)
- Sanofi (United States) (US)
- Tennessee Oncology (US)
- Istanbul Eye Hospital (TR)
- Weill Cornell Medical College in Qatar (QA)
- Tennessee Orthopaedic Clinics (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1111/dom.16591
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Sanofi
- National Institute for Health and Care Research
- NIHR Leicester Biomedical Research Centre